

REFRACTORY ULCERATIONS
IN SMOKERS WITH PAD

Grafix[®]

ONE
viable tissue

THREE
natural components

- Living cells
- Growth factors
- Extracellular matrix

Cryopreserved placental membrane
for wound management



Osiris[®]
THERAPEUTICS, INC.

GRAFIX—CLOSING TREATMENT-REFRACTORY WOUNDS IN SMOKERS WITH PERIPHERAL ARTERIAL DISEASE

Actively smoking patients with a nonhealing lower extremity wound who also suffer from peripheral arterial disease and diabetes are at the greatest risk of ongoing tissue loss, infection, amputation, and potential mortality.¹⁻⁴

THE CLINICAL CASE SERIES⁵

TITLE:
“Wound Closure in Smoking Peripheral Arterial Disease Patients With Treatment-Refractory Ulcerations: A 12-Month Follow-up Case Series.”

OVERVIEW:
This single-center clinical effectiveness review evaluated Grafix for the outpatient management of six recalcitrant lower extremity ulcerations in five actively-smoking patients previously diagnosed with peripheral arterial disease (PAD).

PATIENT DEMOGRAPHICS:	
Age (mean)	58.4 years
Body mass index (mean)	30.9 kg/m ²
Diabetic	80%
Ankle brachial index (mean)	0.7
Fontaine classification for PAD	80% stage II, 20% stage III
Candidate for revascularization	40%
Daily cigarette consumption (mean)	18 cigarettes

WOUND CHARACTERISTICS:	
Wound etiology	<ul style="list-style-type: none">Ischemic and neuroischemic diabetic foot ulcersLeg and foot ulcers with mixed venous and arterial disease
Wound duration prior to study (mean)	53 weeks
Wound area at baseline (mean)	4.6 cm ²




GRAFIX IS A FLEXIBLE, CONFORMING, CRYOPRESERVED MEMBRANE, comprised of three natural components—a collagen-rich extracellular matrix (ECM), growth factors, and living cells such as mesenchymal stem cells (MSCs)—for use as a wound cover.

THE RESULTS⁵


Closure of previously nonhealing ulcerations with Grafix, despite ongoing smoking habits in the presence of PAD and diabetes:

- All patients achieved complete wound closure
- 69.4% wound area reduction at four weeks (mean)
- 7.8 weeks with 7.0 applications of Grafix for wound closure (mean)
- All wounds remained closed at 12-month follow-up
- No wound-related infections or amputations
- No Grafix-related adverse events


CASE 1: MIXED VENOUS, ARTERIAL, AND DIABETIC ULCER OF THE LEFT ANTEROLATERAL LEG




CASE 2: MIXED VENOUS AND ARTERIAL ULCER OF THE RIGHT ANTEROLATERAL LEG




CASE 3: MIXED VENOUS AND ARTERIAL ULCER OF THE LEFT DORSAL MIDFOOT



CASE 4: NEUROISCHEMIC DIABETIC FOOT ULCER OF THE RIGHT PLANTAR FOREFOOT



CASE 5: ISCHEMIC DIABETIC FOOT ULCER OF THE RIGHT FIFTH DIGIT




YOUR NATURAL CHOICE for wound care

Grafix is a cryopreserved membrane comprised of an extracellular matrix (ECM) rich in collagen, growth factors, and living cells—including mesenchymal stem cells (MSCs).

- Designed for application directly to acute and chronic wounds
- Flexible, conforming cover that adheres to complex anatomies
- May be applied over bone, tendon, joint capsule, and muscle
- No need for sutures or Steri-Strip adhesives
- Suitable for a wide variety of hard-to-treat acute and chronic wounds, including but not limited to:
 - Diabetic foot ulcers
 - Burns
 - Deep tunneling wounds
 - Pressure ulcers
 - Pyoderma gangrenosum
 - Surgical dehiscence
 - Trauma
 - Surgical incisions
 - Venous leg ulcers
 - Arterial ulcers

Osiris Therapeutics, Inc. researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs.

GRAFIX IS AVAILABLE IN MULTIPLE SIZES, HELPING YOU REDUCE WASTE AND COST



7015 Albert Einstein Drive
Columbia, MD 21046
1-888-674-9551
www.Osiris.com

REFERENCES: 1. Harding KG. Nonhealing wounds: recalcitrant, chronic, or not understood? *Ostomy Wound Manage.* 2000;46(1A suppl):4S-7S. 2. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed but our methods have not. *J Diabetes Sci Technol.* 2011;5:1591-1595. 3. Jude EB, Oyibo SO, Chalmers N, Bouton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diabetes Care.* 2001;24:1433-1437. 4. Vartanian SM, Robinson KD, Ofili K, et al. Outcomes of neuroischemic wounds treated by a multidisciplinary amputation prevention service. *Ann Vasc Surg.* 2015;29:534-542. 5. Smedley J, Michael G, Tamire Y. Wound Closure in Smoking Peripheral Arterial Disease Patients With Treatment-Refractory Ulcerations: A 12-Month Follow-up Case Series. *Int J Low Extrem Wounds.* 2016;15(4).

© 2018 Osiris Therapeutics, Inc. The Grafix name is a registered trademark of Osiris Therapeutics, Inc. Steri-Strip is a trademark of 3M Company Corp.